Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.2.645

Prognostic Value of Tissue Vascular Endothelial Growth Factor Expression in Bladder Cancer: a Meta-analysis  

Huang, Yu-Jing (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University)
Qi, Wei-Xiang (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University)
He, Ai-Na (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University)
Sun, Yuan-Jue (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University)
Shen, Zan (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University)
Yao, Yang (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.2, 2013 , pp. 645-649 More about this Journal
Abstract
Objective: The prognostic role of vascular endothelial growth factor (VEGF) in bladder cancer remains controversial. This meta-analysis aimed to explore any association between overexpression and survival outcomes. Methods: We systematically searched for studies investigating the relationships between VEGF expression and outcome of bladder cancer patients. Study quality was assessed using the Newcastle-Ottawa Scale. After careful review, survival data were extracted from eligible studies. A meta-analysis was performed to generate combined hazard ratios (HRs) for overall survival (OS), disease-free survival (DFS) and disease-specific survival (DSS). Results: A total of 1,285 patients from 11 studies were included in the analysis. Our results showed that tissue VEGF overexpression in patients with bladder cancer was associated with poor prognosis in terms of OS (HR, 1.843; 95% CI, 1.231-2.759; P = 0.003), DFS (HR, 1.498; 95% CI, 1.255-1.787; P = 0.000) and DSS (HR, 1.562; 95% CI, 0.996-1.00; P = 0.052), though the difference for DSS was not statistically significant. In addition, there was no evidence of publication bias as suggested by Begg's and Egger's tests except for DFS (Begg's test, P = 0.221; Egger's test, P = 0.018). Conclusion: The present meta-analysis indicated elevated VEGF expression to be associated with a poor prognosis in patients with bladder cancer.
Keywords
Vascular endothelial growth factor; prognosis; bladder cancer; meta-analysis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Bernardini S, Fauconnet S, Chabannes E, et al (2001). Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol, 166, 1275-9.   DOI   ScienceOn
2 Chen J, Li T, Wu Y, et al (2011). Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis. J Cancer Res Clin Oncol, 137, 1799-812.   DOI
3 Crew JP, O'Brien T, Bradburn M, et al (1997). Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res, 57, 5281-5.
4 DerSimonian Rand Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.   DOI   ScienceOn
5 Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.   DOI   ScienceOn
6 Ferrara N (2004). Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev, 25, 581-611.   DOI   ScienceOn
7 Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1, 27-31.   DOI   ScienceOn
8 Hanahan Dand Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-74.   DOI   ScienceOn
9 Herrmann E, Eltze E, Bierer S, et al (2007). VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival. Anticancer Res, 27, 3127-33.
10 Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.   DOI   ScienceOn
11 Inoue K, Slaton JW, Karashima T, et al (2000). The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res, 6, 4866-73.
12 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
13 Kanda S, Miyata Y and Kanetake H (2006). Current status and perspective of antiangiogenic therapy for cancer: urinary cancer. Int J Clin Oncol, 11, 90-107.   DOI
14 Li Z, Qi F, Qi L, et al (2011). VEGF-C as a decision-making biomarker for selected patients with invasive bladder cancer who underwent bladder-preserving radical surgery. Arch Med Res, 42, 405-11.   DOI   ScienceOn
15 Ma Y, Hou Y, Liu B, et al (2010). Intratumoral lymphatics and lymphatic vessel invasion detected by D2-40 are essential for lymph node metastasis in bladder transitional cell carcinoma. Anat Rec (Hoboken), 293, 1847-54.   DOI
16 Nadaoka J, Horikawa Y, Saito M, et al (2008). Prognostic significance of HIF-1 alpha polymorphisms in transitional cell carcinoma of the bladder. Int J Cancer, 122, 1297-302.
17 Parmar MK, Torri V and Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.   DOI
18 Pignot G, Bieche I, Vacher S, et al (2009). Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker. Eur Urol, 56, 678-88.   DOI   ScienceOn
19 Qu JT, Wang M, He HL, et al (2012). The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review. J Cancer Res Clin Oncol, 138, 819-25.   DOI
20 Schoenleber SJ, Kurtz DM, Talwalkar JA, et al (2009). Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer, 100, 1385-92.   DOI   ScienceOn
21 Shariat SF, Youssef RF, Gupta A, et al (2010). Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol, 183, 1744-50.   DOI   ScienceOn
22 Theodoropoulos VE, Lazaris A, Sofras F, et al (2004). Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol, 46, 200-8.   DOI   ScienceOn
23 Suzuki K, Morita T and Tokue A (2005). Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Int J Urol, 12, 152-8.   DOI   ScienceOn
24 Szarvas T, Jager T, Droste F, et al (2009). Serum levels of angiogenic factors and their prognostic relevance in bladder cancer. Pathol Oncol Res, 15, 193-201.   DOI   ScienceOn
25 Szarvas T, Jager T, Totsch M, et al (2008). Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer. Clin Cancer Res, 14, 8253-62.   DOI   ScienceOn
26 Thieblemont C, Fendler JP, Trillet-Lenoir V, et al (1996). [Prognostic factors of survival in infiltrating urothelial bladder carcinoma. A retrospective study of 158 patients treated by radical cystectomy]. Bull Cancer, 83, 139-46.
27 van Rhijn BW (2012). Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer. Urol Oncol, 30, 518-23.   DOI   ScienceOn
28 Wells GA, Brodsky L, O'Connell D, et al (2003). An Evaluation of the Newcastle Ottawa Scale: An Assessment Tool for Evaluating the Quality of Non-Randomized Studies. In XI Cochrane Colloquium Vol. O-63. p 26. Barcelona: XI International Cochrane Colloquium Book of Abstracts.
29 Yang CC, Chu KC and Yeh WM (2004). The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol, 22, 1-6.   DOI   ScienceOn
30 Youssef RFand Lotan Y (2011). Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer. ScientificWorldJournal, 11, 369-81.   DOI   ScienceOn
31 Zu X, Tang Z, Li Y, et al (2006). Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int, 98, 1090-3.   DOI   ScienceOn
32 Yu L, Deng L, Li J, et al (2012). The prognostic value of vascular endothelial growth factor in ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol, 128, 391-6.
33 Zaravinos A, Volanis D, Lambrou GI, et al (2012). Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder. Oncol Rep, 28, 1159-66.
34 Zhan P, Wang J, Lv XJ, et al (2009). Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol, 4, 1094-103.   DOI   ScienceOn